ESTRO 2021 Abstract Book

S203

ESTRO 2021

OC-0297 Preliminary results of the Italian Retrospective Study on exclusive radiotherapy for vulvar cancer C. Casà 1 , L. Tagliaferri 1 , M. Ferioli 2 , V. Lancellotta 1 , M. Boccardi 3 , A. Cerrotta 4 , F. Tortoreto 5 , E. Ippolito 6 , C. Laliscia 7 , A. Huscher 8 , S. Gribaudo 9 , A.G. Morganti 2 , R. Lazzari 10 , G. Garganese 11 , G. Macchia 3 1 Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy; 2 IRCCS Azienda Ospedaliero-Universitaria di Bologna - Alma Mater Studiorum University of Bologna, Radiation Oncology, Department of Experimental, Diagnostic and Specialty Medicine – DIMES, Bologna, Italy; 3 Gemelli Molise Hospital – Università Cattolica del Sacro Cuore, Radiation Oncology Unit, Campobasso, Italy; 4 Fondazione IRCCS Istituto Nazionale dei Tumori, Radiotherapy Unit, Milan, Italy; 5 Ospedale San Pietro Fatebenefratelli, Radiotherapy Unit, Rome, Italy; 6 Università Campus Bio-Medico, Radiation Oncology, Rome, Italy; 7 University of Pisa, Department of New Technologies and Translational Research, Division of Radiation Oncology, Pisa, Italy; 8 Fondazione Poliambulanza, U.O. di Radioterapia Oncologica “Guido Berlucchi", Brescia, Italy; 9 A.O.U "Città della Salute e della Scienza", Dipartimento di Oncologia P.O. S. Anna - SS Radioterapia, Turin, Italy; 10 IEO European Institute of Oncology IRCCS, Division of Radiotherapy, Milan, Italy; 11 Mater Olbia Hospital, Gynecology and Breast Care Center, Olbia, Italy Purpose or Objective Vulvar cancer is a relatively uncommon type of gynecologic cancer. The aim of this study was to define efficacy and safety of exclusive (chemo)radiotherapy (eRT) in a large, real-world data set of patients with vulvar cancer (VC). We mainly focused on treatment prescription among radiotherapy centers joining the Observational itaLian stuDy on vuLvar cAncer radical raDiotherapY (OLDLADY) project endorsed by the GYN study group of the AIRO (Italian Association of Radiotherapy and Clinical Oncology). Materials and Methods Data from VC patients treated by eRT in seven Italian radiotherapy units from January 2010 to December 2018 were retrospectively collected. The staging, treatment prescription, clinical outcomes and toxicities were investigated and analysed. Results The study population accounted for 90 patients, with a median age of 76 (range 32-92) years (Table 1). The collected data have shown a large heterogeneity in therapeutic approaches to VC patients in terms of prescribed volumes, and radiotherapy doses, with several chemotherapy schedules proposed. The severe acute toxicity was mainly cutaneous (26%), and a low rate of severe skin fibrosis (4.4%) was registered. With a median follow-up of 10 months (range 1-199 months), the 24-month actuarial LC rate, disease free and overall survival were 42.2%, 40%, and 36.7%, respectively, as reported in Figure 1. Table 1. Study population